Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ITCH deficiency protects from diet-induced obesity

  • Marino, Arianna
  • Moreno-Navarrete, José Maria
  • Gómez-Serrano, María
  • Peral, Belén
  • Fernández-Real, José M.
  • Federici, Massimo
et al., Classically activated macrophages (M1) secrete proinflammatory cytokine and are predominant in obese adipose tissue. M2 macrophages, prevalent in lean adipose tissue, are induced by IL-13 and IL-4, mainly secreted by Th2 lymphocytes, and produce the anti-inflammatory cytokine IL-10. ITCH is a ubiquitously expressed E3 ubiquitin ligase involved in T-cell differentiation and in a wide range of inflammatory pathways. ITCH downregulation in lymphocytes causes aberrant Th2 differentiation. To investigate the role of Th2/M2 polarization in obesityrelated inflammation and insulin resistance, we compared wild-type and Itch2/2 mice in a context of diet-induced obesity (high-fat diet [HFD]). When subjected to HFD, Itch2/2 mice did not show an increase in body weight or insulin resistance; calorimetric analysis suggested an accelerated metabolism. The molecular analysis of metabolically active tissue revealed increased levels of M2 markers and genes involved in fatty acid oxidation. Histological examination of livers from Itch2/2 mice suggested that ITCH deficiency protects mice from obesity-related nonalcoholic fatty liver disease. We also found a negative correlation between ITCH and M2 marker expression in human adipose tissues. Taken together, our data indicate that ITCH E3 ubiquitin ligase deficiency protects from the metabolic disorder caused by obesity., This study was funded in part by Fondazione Roma 2008, ESFD/Lilly 2012, AIRC 2012 Project IG 13163, FP7-Health-241913 FLORINASH, FP-7 EURHYTHDIA, and PRIN 2009FATXW3_002 to M.Fe.; SAF-2012-33014 from Ministerio de Economía y Competitividad, Spain, to B.P.; and Medical Research Council, U.K., grants ACC12, MIUR/PRIN (20078P7T3K_001)/FIRB (RBIP06LCA9_0023, RBIP06LCA9_0C), AIRC (2011-IG11955), and AIRC 5xmille (MCO #9979), Telethon grant GGPO9133, Ministero della Salute, and IDI-IRCCS (RF08 c.15, RF07 c.57) to G.M., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome

  • Mayneris-Perxachs, Jordi
  • Cardellini, Marina
  • Hoyles, Lesley
  • Latorre, Jèssica
  • Davato, Francesca
  • Moreno-Navarrete, José Maria
  • Arnoriaga-Rodríguez, María
  • Serino, Matteo
  • Abbott, James
  • Barton, Richard H.
  • Puig, Josep
  • Fernández-Real, Xavier
  • Ricart, Wifredo
  • Tomlinson, Christopher
  • Woodbridge, Mark
  • Gentileschi, Paolo
  • Butcher, Sarah A.
  • Holmes, Elaine
  • Nicholson, Jeremy K.
  • Pérez-Brocal, Vicente
  • Moya, Andrés
  • Mc Clain, Donald
  • Burcelin, Rémy
  • Dumas, Marc-Emmanuel
  • Federici, Massimo
  • Fernández-Real, José Manuel
[Background]: The gut microbiome and iron status are known to play a role in the pathophysiology of non-alcoholic fatty liver disease (NAFLD), although their complex interaction remains unclear., [Results]: Here, we applied an integrative systems medicine approach (faecal metagenomics, plasma and urine metabolomics, hepatic transcriptomics) in 2 well-characterised human cohorts of subjects with obesity (discovery n = 49 and validation n = 628) and an independent cohort formed by both individuals with and without obesity (n = 130), combined with in vitro and animal models. Serum ferritin levels, as a markers of liver iron stores, were positively associated with liver fat accumulation in parallel with lower gut microbial gene richness, composition and functionality. Specifically, ferritin had strong negative associations with the Pasteurellaceae, Leuconostocaceae and Micrococcaea families. It also had consistent negative associations with several Veillonella, Bifidobacterium and Lactobacillus species, but positive associations with Bacteroides and Prevotella spp. Notably, the ferritin-associated bacterial families had a strong correlation with iron-related liver genes. In addition, several bacterial functions related to iron metabolism (transport, chelation, heme and siderophore biosynthesis) and NAFLD (fatty acid and glutathione biosynthesis) were also associated with the host serum ferritin levels. This iron-related microbiome signature was linked to a transcriptomic and metabolomic signature associated to the degree of liver fat accumulation through hepatic glucose metabolism. In particular, we found a consistent association among serum ferritin, Pasteurellaceae and Micrococcacea families, bacterial functions involved in histidine transport, the host circulating histidine levels and the liver expression of GYS2 and SEC24B. Serum ferritin was also related to bacterial glycine transporters, the host glycine serum levels and the liver expression of glycine transporters. The transcriptomic findings were replicated in human primary hepatocytes, where iron supplementation also led to triglycerides accumulation and induced the expression of lipid and iron metabolism genes in synergy with palmitic acid. We further explored the direct impact of the microbiome on iron metabolism and liver fact accumulation through transplantation of faecal microbiota into recipient’s mice. In line with the results in humans, transplantation from ‘high ferritin donors’ resulted in alterations in several genes related to iron metabolism and fatty acid accumulation in recipient’s mice., [Conclusions]: Altogether, a significant interplay among the gut microbiome, iron status and liver fat accumulation is revealed, with potential significance for target therapies., This work was supported by EU-FP7 FLORINASH (Health-F2-2009-241913) to R.B., M.F., J.M.F.R., E.H. and J.K.N. Infrastructure support was provided by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). L.H. was in receipt of an MRC Intermediate Research Fellowship in Data Science (grant number MR/L01632X/1, UK Med-Bio). This work was also partly supported by funding to M.-E.D. (EU METACARDIS under agreement HEALTH-F4-2012-305312, Neuron II under agreement 291840 and the MRC MR/M501797/1) and by grants from the French National Research Agency (ANR-10-LABX-46 [European Genomics Institute for Diabetes]), from the National Center for Precision Diabetic Medicine – PreciDIAB, which is jointly supported by the French National Agency for Research (ANR-18-IBHU-0001), by the European Union (FEDER), by the Hauts-de-France Regional Council (Agreement 20001891/NP0025517) and by the European Metropolis of Lille (MEL, Agreement 2019_ESR_11) and by Isite ULNE (R-002-20-TALENT-DUMAS), also jointly funded by ANR (ANR-16-IDEX-0004-ULNE) the Hauts-de-France Regional Council (Agreement 20002045) and by the European Metropolis of Lille (MEL). J.M.-P. is funded by the Miguel Servet Program from the Instituto de Salud Carlos III (ISCIII CP18/00009), co-funded by the European Social Fund ‘Investing in your future’. María Arnoriaga Rodríguez is funded by a predoctoral Río Hortega contract (CM19/00190, co-funded by European Social Fund ‘Investing in your future’) from the Instituto de Salud Carlos III, Spain. This work was supported by grants to AM from the Spanish Ministry of Science and Innovation (PID2019-105969GB-I00) and Generalitat Valenciana (project Prometeo/2018/133)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism

  • Castells-Nobau, Anna
  • Moreno-Navarrete, José Maria
  • Vega-Correa, Lisset de la
  • Puig, Irene
  • Arnoriaga-Rodríguez, María
  • Pérez-Brocal, Vicente
  • Moya, Andrés
  • Fernández-Real, José Manuel
  • Mayneris-Perxachs, Jordi
Castells-Nobau A., et al., [Background]: The microbiota is emerging as a key factor in the predisposition to insulin resistance and obesity., [Objective]: To understand the interplay among gut microbiota and insulin sensitivity in multiple tissues., [Design]: Integrative multiomics and multitissue approach across six studies, combining euglycaemic clamp measurements (used in four of the six studies) with other measurements of glucose metabolism and insulin resistance (glycated haemoglobin (HbA1c) and fasting glucose)., [Results]: Several genera and species from the Proteobacteria phylum were consistently negatively associated with insulin sensitivity in four studies (ADIPOINST, n=15; IRONMET, n=121, FLORINASH, n=67 and FLOROMIDIA, n=24). Transcriptomic analysis of the jejunum, ileum and colon revealed T cell-related signatures positively linked to insulin sensitivity. Proteobacteria in the ileum and colon were positively associated with HbA1c but negatively with the number of T cells. Jejunal deoxycholic acid was negatively associated with insulin sensitivity. Transcriptomics of subcutaneous adipose tissue (ADIPOMIT, n=740) and visceral adipose tissue (VAT) (ADIPOINST, n=29) revealed T cell-related signatures linked to HbA1c and insulin sensitivity, respectively. VAT Proteobacteria were negatively associated with insulin sensitivity. Multiomics and multitissue integration in the ADIPOINST and FLORINASH studies linked faecal Proteobacteria with jejunal and liver deoxycholic acid, as well as jejunal, VAT and liver transcriptomic signatures involved in the actin cytoskeleton, insulin and T cell signalling. Fasting glucose was consistently linked to interferon-induced genes and antiviral responses in the intestine and VAT. Studies in Drosophila melanogaster validated these human insulin sensitivity-associated changes., [Conclusion]: These data provide comprehensive insights into the microbiome-gut-adipose-liver axis and its impact on systemic insulin action, suggesting potential therapeutic targets.Cite Now., This work was partly supported by EU- FP7 FLORINASH (Health- F2- 2009- 241913) to RB, MF and JMFR, by Instituto de Salud Carlos III (Madrid, Spain) through the projects PI15/01934, PI18/01022, PI21/01361 and PMP21/00072 (co- funded by the European Union/Plan de Recuperación, Transformación y Resiliencia) to JMFR, PI19/01712 to JMM- N, and PI20/01090 and PI23/00575 to JM- P (co- funded by the European Union under the European Regional Development Fund (FEDER). ’A way to make Europe’), the project CNS2023- 144218 funded by MCIN/ AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR to JM- P and Generalitat de Catalunya 2021 SGR 01263. This work has also been co- f inanced by the Spanish Ministry of Science, Innovation and Universities with funds from the European Union NextGenerationEU, from the Recovery, Transformation and Resilience Plan (PRTR- C17.I1) and from the Autonomous Community of Catalonia within the framework of the Biotechnology Plan Applied to Health through the project PPCC- ADGUT to JM- P. JM- P and ACN are funded by Instituto de Salud Carlos III (Madrid, Spain) through the Miguel Servet Program CP18/00009 and Sara Borrell Program CD20/00051 (co- funded by the European Union under the European Social Fund ’Investing in your future’), respectively. IDIBGI is a CERCA centre from the ’CERCA Programme/Generalitat de Catalunya’. The Cohort SIMMUNIDIA has been promoted by the Rangueil Hospital of Toulouse, France and received an essential f inancial support from the Federation Française de Recherche en Diabetologie, technical support from the departments of Gastroenterology and Diabetes. This study has been granted from the Fondation Francophone pour la Recherche sur le Diabète, sponsored by the FFD, Abbott, AstraZeneca, Lilly, MSD, Novo Nordisk and Sanofi. We thank Emeline Lhuilier at GeT- Santé facility (I2MC, Inserm, Génome et Transcriptome, GenoToul, Toulouse, France) for its contribution to the sequencing data (US1426, INRAE, Génome et Transcriptome, GenoToul, Toulouse, France) and Vaiomer SAS (Labège innopole France) for 16SrRNA sequencing. We thank Vincent Azalbert for then immune cell preparation. We thank Professor Louis Buscail, Professor Barbara Bournet and Mrs Emilie Bergereau (Department of Gastroenterology, CHU de Toulouse, Toulouse, France) for their contribution to the SIMMUNIDIA study. FLORINASH is also funded by GutsUK and Diabetes UK grants to M- ED and supported by the NIHR Imperial Biomedical Research Centre and by grants from the French National Research Agency (ANR- 10- LABX- 46 (European Genomics Institute for Diabetes)), the National Center for Precision Diabetic Medicine, which is jointly supported by the French National Agency for Research (ANR- 18- IBHU- 0001), the European Union (FEDER), the Hauts- de- France Regional Council (Agreement 20001891/NP0025517), the European Metropolis of Lille (agreement 2019_ ESR_11) and site ULNE (R- 00220- TALENT- DUMAS), which is also jointly funded by ANR (ANR- 16- IDEX0004- ULNE), the Hauts- de- France Regional Council (20002845) and the European Metropolis of Lille. This research was conducted within the context of the CNRS–ULille–Imperial International Research Project in Integrative Metabolism ’METABO- LIC’., Peer reviewed